trending Market Intelligence /marketintelligence/en/news-insights/trending/V4w9O98pqnYQAI97UKV9cw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers, bluebird bio drug reduces blood cancer in mid-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bristol-Myers, bluebird bio drug reduces blood cancer in mid-stage study

Bristol-Myers Squibb Co. and bluebird bio Inc. said its experimental blood cancer treatment ide-cel reduced the disease and extended life in patients during a mid-stage study.

SNL Image

The companies were evaluating the chimeric antigen receptor T cell, or CAR-T cell, therapy in patients with relapsed and refractory multiple myeloma who have received at least three prior treatments. Multiple myeloma is an incurable blood cancer that forms in plasma cells, which are responsible for producing antibodies.

The companies evaluated three doses of the CAR-T cell therapy in the open-label phase 2 study, dubbed as KarMMa. Ide-cel achieved the primary goal of reducing the disease in patients, also known as the overall response rate, across all dose groups.

The treatment also met the key secondary endpoint of the study by leaving no detectable cancer, known as complete response.

CAR-T cell therapies are a complex and expensive form of cancer treatment that takes a patient's own immune cells and modifies them to fight cancer when infused back into the body.

The U.S. Food and Drug Administration has approved Novartis AG's Kymriah and Gilead Sciences Inc.'s Yescarta to treat certain cancers. Both CAR-T cell therapies cost upward of $300,000.

SNL Image